Mohammad Rahmanian

Dr. Mohammad Rahmanian


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Regenerative Therapy
Verified
Journal Article
Open access
FKFatemeh Abbasi Kakroodi
Fatemeh Abbasi Kakroodi
EKElaheh Khodadoust
Elaheh Khodadoust
MAMarzieh Alizadeh
Marzieh Alizadeh
RTReyhaneh Sadat Hayaei Tehrani
Reyhaneh Sadat Hayaei Tehrani
PSPedram Asadi Sarabi
Pedram Asadi Sarabi
Massoud VosoughMassoud Vosough
Massoud Vosough
Advanced therapy medicinal products (ATMPs) represent a groundbreaking category of medications that utilize biological-based products to treat or replace damaged organs. It offers potential solutions for complex diseases through gene therapy, somatic cell therapy, tissue engineering, and combined therapies. Although ATMPs have offered significant improvement for a variety of severe illnesses, their progressive development is faced with numerous challenges. Some of these challenges are current complexities in their manufacturing, such as scaling up, scaling out, product efficacy, packaging, storage, stability, and logistic concerns. Other challenges include manufacturing, efficacy, and scaling up of ATMPs, as well as establishing Good Manufacturing Practice (GMP)-compliant processes that align with product specifications derived from non-clinical studies conducted under Good Laboratory Practice (GLP). Additionally, safety concerns such as tumorigenesis are potential. Regulatory and ethical concerns, along with the need for standardization and clear clinical guidelines, are also critical obstacles. To address these challenges, novel technologies such as organoids, artificial intelligence, dynamic culture systems, and biobanking are being explored, providing new opportunities to enhance the consistency, scalability, and precision of ATMP production. Development in artificial intelligence (AI) technology helped scientists to address monitoring concerns, automation, and data management. Introducing advanced guidelines in biobanking helps researchers to overcome the storage and stability concerns. Organoid technology holds a significant promise in overcoming the challenges associated with preclinical and modeling of ATMPs by providing more accurate models for diseases, drug screening, and personalized medicine. This article reviews the current challenges in ATMP manufacturing and application, highlights the advancements in technology that are paving the way for improved therapeutic strategies, and offers future perspectives on overcoming these barriers.

22 October 2025 in Health Science Reports
Verified
Journal Article
Open access
SSSaeid Safiri
Saeid Safiri
FAFatemeh Amiri
Fatemeh Amiri
NKNahid Karamzad
Nahid Karamzad
MSMark J. M. Sullman
Mark J. M. Sullman
MRMohammad Rahmanian
Mohammad Rahmanian
AKAli-Asghar Kolahi
Ali-Asghar Kolahi
Background and Aims: Osteopenia and osteoporosis present a significant global public health challenge. This study analyses the global, regional, and national burden of disease attributable to low bone mineral density, including both osteopenia and osteoporosis, across 204 countries and territories from 1990 to 2021. Methods: Data were used to quantify deaths and disability‐adjusted life years (DALYs) linked to osteopenia and osteoporosis. Results: In 2021, osteopenia and osteoporosis were responsible for 459,661 deaths and 17.3 million DALYs globally, with population attributable fractions of 0.7% and 0.6%, respectively. The global age‐standardized death rate was 5.7 per 100,000, while the age‐standardized DALY rate was 205 per 100,000, reflecting declines of 9.4% and 14.8%, respectively, from 1990 to 2021. The highest age‐standardized DALY rates were seen in Saudi Arabia and India, while the lowest were in Azerbaijan and Jamaica. Significant increases in DALY rates were noted in Lesotho and the Netherlands, whereas the largest decreases occurred in Hungary and Taiwan. DALY rates for osteopenia and osteoporosis were highest in the 95+ age group for both sexes, with females generally experiencing higher rates, particularly in older age groups. The main contributing causes varied by age, with falls being the leading cause in the 80–84 age group, road injuries in the 40–44 age group, and exposure to mechanical forces in the 50–54 age group. A negative correlation was observed between regional socio‐demographic index and age‐standardized DALY rates from 1990 to 2021. Conclusion: Addressing the global burden of osteopenia and osteoporosis requires targeted interventions, further research, and efforts to reduce regional disparities and improve healthcare access.

22 July 2025 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
AAAmir Azimi
Amir Azimi
AJAmir Ghaffari Jolfayi
Amir Ghaffari Jolfayi
VRVida Rezayifar
Vida Rezayifar
FAFatemeh Ateen
Fatemeh Ateen
HFHanie Hosseini Fard
Hanie Hosseini Fard
MRMohammad Rahmanian
Mohammad Rahmanian

20 November 2025 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
RZRasa Zafari
Rasa Zafari
NGNooshin Goudarzi
Nooshin Goudarzi
AKAmirhossein Kamroo
Amirhossein Kamroo
MTMahdi Falah Tafti
Mahdi Falah Tafti
AGATOUSA GHORBANI
ATOUSA GHORBANI
MNMarjan Nassiri-Asl
Marjan Nassiri-Asl
Neurodegenerative diseases (NDDs) like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are growing global health concerns characterized by progressive cognitive and motor impairments. Recent studies have reported the role of gut microbiota and its interaction with the microbiome-gut-brain axis (MGBA) in these disorders. Dietary polyphenols possess antioxidant and antiinflammatory properties, which might modulate gut microbiota and attenuate the progression of these NDDs by acting on MGBA. This systematic review evaluates the effects of polyphenols on gut microbiota, their metabolites, and gut microbiota-related mechanisms in NDDs. Following PRISMA guidelines, a comprehensive literature search was conducted across Embase, PubMed, Scopus, and Google Scholar databases. Studies investigating the effects of polyphenols on gut microbial metabolites and composition in NDDs were reviewed. Data were extracted on study design, interventions, and outcomes, and quality was assessed using SYRCLE’s risk of bias tool. Twenty-six animal studies met the inclusion criteria. Polyphenols favored microbial beneficial changes, increased short-chain fatty acids (SCFAs), and reduced neuroinflammation by modulating inflammatory cytokine profiles (IL-1β, TNF-α, and IL-6 reduction). In NDD animal models, memory and motor functions were observed to have improved, likely due to reduced oxidative stress, as well as decreased amyloid accumulation and improved gut and brain integrity. The interventions enriched beneficial genera (Bacteroidetes, Bifidobacterium, Lactobacillus, Rikenellaceae, and Alloprevotella) and reduced detrimental groups (Helicobacter, Bacteroidaceae, Rikenella, and Prevotella). The evidence suggests polyphenols may influence the gut microbiota and, in turn, alleviate NDD symptoms. However, we need to confirm this in more studies, especially in human studies.

30 May 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
IVIman Elahi Vahed
Iman Elahi Vahed
MMMahsa Moshgelgosha
Mahsa Moshgelgosha
AKAbdolmajid Kor
Abdolmajid Kor
MMMona Minadi
Mona Minadi
FEFaezeh Ebrahimi
Faezeh Ebrahimi
MRMohammad Rahmanian
Mohammad Rahmanian
Colorectal cancer ranks as the third most frequently diagnosed cancer globally. Adipokines, including adiponectin and leptin, are believed to play a vital role in the development and progression of tumors. This study aimed to clarify the association between circulating adiponectin and leptin concentrations and the risk of colorectal cancer and adenoma. A detailed literature review was conducted in different databases, including Google Scholar, Web of Science, Scopus, and PubMed. Articles measuring serum concentrations of adiponectin and leptin in colorectal adenoma or cancer patients were analyzed. Pooled odds ratios (ORs) and their related 95% confidence intervals (CIs) were estimated through a random-effects meta-analysis. In total, 30 articles were analyzed. According to the meta-analysis, higher adiponectin concentrations were inversely linked to a reduced CRC risk (OR: 0.85, 95% CI: 0.74–0.96), particularly in men. However, no notable connection was detected between higher leptin concentrations and risk of CRC (OR: 1.12, 95% CI: 0.96–1.31). In subgroup analyses, BMI adjustment reinforced the negative association between higher adiponectin levels and risk of CRC, while insulin adjustment yielded non-significant results. Additionally, higher leptin levels revealed a meaningful relationship with colorectal adenoma risk (OR: 1.39, 95% CI: 1.06–1.84), whereas higher levels of adiponectin were not significantly linked to adenoma (OR: 0.79, 95% CI: 0.46–1.36). According to this meta-analysis, elevated adiponectin concentrations may play a protective role against CRC, while leptin could potentially contribute to an elevated colorectal adenoma risk. Further studies are required to explore the potential mechanisms underlying adipokine-mediated colorectal carcinogenesis.

31 March 2025 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
Ariyan Ayati FiroozabadiAriyan Ayati Firoozabadi
Ariyan Ayati Firoozabadi
SKSajad Khodabandelu
Sajad Khodabandelu
SKSara Khaleghi
Sara Khaleghi
ANAnita Nourmohammadi
Anita Nourmohammadi
FJFarnaz Jafari
Farnaz Jafari
MRMohammad Rahmanian
Mohammad Rahmanian
Several earlier studies have shown that IBD (including its two subtypes, ulcerative colitis (UC) and Crohn’s disease (CD)) increases the risk of periodontal disease. This study aimed to evaluate the relevance among periodontitis and IBD subcategories. This study was conducted based on PRISMA guidelines. The Web of Science, PubMed, Google Scholar, and Scopus databases were searched up to February 2024 using pertinent keywords. Case series, review articles, and animal studies were excluded. The risk of bias in this research was evaluated through the Joanna Briggs Institute (JBI) criteria. The meta-analysis was conducted using R statistical software. A total of 9134 patients within 13 studies after the screening process were evaluated. Our study has shown that periodontitis is significantly more prevalent among IBD patients (UC and CD). According to prior meta-analyses, PD morbidity was found to be significantly high among CD patients (OR: 4.30; 95% CI: 3.72–4.98; I2 = 0%). Similarly, UC elevated PD risk (OR: 4.55; 95% CI: 3.76–5.50; I2 = 0%). The risk of periodontitis was not significantly different between CD and UC patients (OR: 0.96; 95% CI: 0.65–1.43; I2 = 34%). UC and CD patients were more likely to develop periodontitis, with low heterogeneity between studies, while the prevalence of periodontitis among UC and CD patients was not meaningfully different. The higher risk of periodontitis in patients with IBD indicates the necessity of screening for periodontitis. Considering the various oral manifestations and poor quality of life associated with IBD, it is important to be aware of the symptoms of periodontitis.